{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T05:25:07Z","timestamp":1789881907373,"version":"4.0.1"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T00:00:00Z","timestamp":1767312000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ebiom.2026.106121","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T19:58:57Z","timestamp":1768593537000},"page":"106121","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Generation and characterisation of a humanised GLP-1 receptor mouse model for translational drug development"],"prefix":"10.1016","volume":"124","author":[{"given":"Nina","family":"Sonne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micaela","family":"Roque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Line Fisker","family":"Zachariassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trine","family":"Porsgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne E.","family":"Pors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Cavalera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Osborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ditte Dencker","family":"Thorbek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malene Lundgaard","family":"Riis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Feigh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Quinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibragim","family":"Gaidarov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Anthony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3732-0281","authenticated-orcid":false,"given":"Henrik H.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Tozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ebiom.2026.106121_bib1","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab"},{"key":"10.1016\/j.ebiom.2026.106121_bib2","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","article-title":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","volume":"28","author":"Garvey","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.ebiom.2026.106121_bib3","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ebiom.2026.106121_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101171","article-title":"Whole-brain activation signatures of weight-lowering drugs","volume":"47","author":"Hansen","year":"2021","journal-title":"Mol Metab"},{"key":"10.1016\/j.ebiom.2026.106121_bib5","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.133429","article-title":"Semaglutide lowers body weight in rodents via distributed neural pathways","volume":"5","author":"Gabery","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.ebiom.2026.106121_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101351","article-title":"GLP-1 physiology informs the pharmacotherapy of obesity","volume":"57","author":"Drucker","year":"2022","journal-title":"Mol Metab"},{"key":"10.1016\/j.ebiom.2026.106121_bib7","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ebiom.2026.106121_bib8","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ebiom.2026.106121_bib9","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ebiom.2026.106121_bib11","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0140-6736(23)01185-6","article-title":"Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"402","author":"Knop","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ebiom.2026.106121_bib12","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s13340-019-00423-8","article-title":"The development of oral semaglutide, an oral GLP-1 analog, for the treatment of type 2 diabetes","volume":"11","author":"Rasmussen","year":"2020","journal-title":"Diabetol Int"},{"key":"10.1016\/j.ebiom.2026.106121_bib13","doi-asserted-by":"crossref","first-page":"29959","DOI":"10.1073\/pnas.2014879117","article-title":"Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist","volume":"117","author":"Kawai","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ebiom.2026.106121_bib14","doi-asserted-by":"crossref","first-page":"8208","DOI":"10.1021\/acs.jmedchem.1c01856","article-title":"A small-molecule oral agonist of the human glucagon-like peptide-1 receptor","volume":"65","author":"Griffith","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.ebiom.2026.106121_bib15","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1111\/dom.15383","volume":"26","author":"Wu","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ebiom.2026.106121_bib16","doi-asserted-by":"crossref","first-page":"785P","DOI":"10.2337\/db25-785-P","article-title":"785-P: First Report on the Small Molecule Oral GLP-1 Receptor Agonist RGT-075 in Obesity\u2014A Randomized, Placebo-Controlled Phase 2a Proof-of-Concept Twelve-Week Study","volume":"74","author":"Rosenstock","year":"2025","journal-title":"Diabetes"},{"key":"10.1016\/j.ebiom.2026.106121_bib17","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJMoa2302392","article-title":"Daily oral GLP-1 receptor agonist orforglipron for adults with obesity","volume":"389","author":"Wharton","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ebiom.2026.106121_bib18","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S0140-6736(23)01302-8","article-title":"Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study","volume":"402","author":"Frias","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ebiom.2026.106121_bib19","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1111\/dom.15150","article-title":"Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: a Phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes","volume":"25","author":"Pratt","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ebiom.2026.106121_bib20","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1111\/dom.15168","article-title":"Tolerability, safety and pharmacodynamics of oral, small-molecule glucagon-like peptide-1 receptor agonist danuglipron for type 2 diabetes: a 12-week, randomized, placebo-controlled, Phase 2 study comparing different dose-escalation schemes","volume":"25","author":"Saxena","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ebiom.2026.106121_bib21","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.14493","article-title":"Efficacy and safety of oral small molecule glucagon-like peptide 1 receptor agonist danuglipron for glycemic control among patients with type 2 diabetes: a randomized clinical trial","volume":"6","author":"Saxena","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ebiom.2026.106121_bib22","doi-asserted-by":"crossref","first-page":"4915","DOI":"10.1111\/dom.16534","article-title":"Efficacy and safety of danuglipron (PF-06882961) in adults with obesity: a randomized, placebo-controlled, dose-ranging phase 2b study","volume":"27","author":"Buckeridge","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ebiom.2026.106121_bib23","doi-asserted-by":"crossref","first-page":"6314","DOI":"10.1111\/dom.70022","article-title":"Orforglipron, an oral non-peptide glucagon-like peptide-1 receptor agonist, improves markers of \u03b2-cell function and insulin sensitivity in type 2 diabetes","volume":"27","author":"Rosenstock","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ebiom.2026.106121_bib24","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1056\/NEJMoa2505669","article-title":"Orforglipron, an oral small-molecule GLP-1 receptor agonist, in early type 2 diabetes","volume":"393","author":"Rosenstock","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ebiom.2026.106121_bib25","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1080\/14656566.2024.2356254","article-title":"Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now?","volume":"25","author":"Gogineni","year":"2024","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.ebiom.2026.106121_bib26","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41366-024-01473-y","article-title":"What is the pipeline for future medications for obesity?","volume":"49","author":"Melson","year":"2024","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/j.ebiom.2026.106121_bib27","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/bph.15446","article-title":"Non-peptide agonists and positive allosteric modulators of glucagon-like peptide-1 receptors: alternative approaches for treatment of type 2 diabetes","volume":"179","author":"Malik","year":"2022","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.ebiom.2026.106121_bib28","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.molcel.2020.09.020","article-title":"Differential GLP-1R binding and activation by peptide and non-peptide agonists","volume":"80","author":"Zhang","year":"2020","journal-title":"Mol Cell"},{"key":"10.1016\/j.ebiom.2026.106121_bib29","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/9780470942390.mo150178","article-title":"Generating mouse models using CRISPR-Cas9-Mediated genome editing","volume":"6","author":"Qin","year":"2016","journal-title":"Curr Protoc Mouse Biol"},{"key":"10.1016\/j.ebiom.2026.106121_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103739","article-title":"Reagents and models for detecting endogenous GLP1R and GIPR","volume":"74","author":"Ast","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ebiom.2026.106121_bib31","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s12021-020-09490-8","article-title":"An optimized mouse brain atlas for automated mapping and quantification of neuronal activity using iDISCO+ and light sheet fluorescence microscopy","volume":"19","author":"Perens","year":"2021","journal-title":"Neuroinformatics"},{"key":"10.1016\/j.ebiom.2026.106121_bib32","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3389\/fendo.2019.00155","article-title":"The discovery and development of liraglutide and semaglutide","volume":"10","author":"Knudsen","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.ebiom.2026.106121_bib33","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1007\/s00125-017-4289-0","article-title":"Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial","volume":"60","author":"Kapitza","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/j.ebiom.2026.106121_bib34","doi-asserted-by":"crossref","first-page":"19650","DOI":"10.1016\/S0021-9258(19)36565-2","article-title":"Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells","volume":"268","author":"G\u00f6ke","year":"1993","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ebiom.2026.106121_bib35","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1111\/dom.14280","article-title":"The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity","volume":"23","author":"Friedrichsen","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ebiom.2026.106121_bib36","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/dom.14551","article-title":"Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss","volume":"24","author":"Wharton","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ebiom.2026.106121_bib37","doi-asserted-by":"crossref","first-page":"10470","DOI":"10.1523\/JNEUROSCI.22-23-10470.2002","article-title":"The diverse roles of specific GLP-1 receptors in the control of food intake and the response to visceral illness","volume":"22","author":"Kinzig","year":"2002","journal-title":"J Neurosci"},{"key":"10.1016\/j.ebiom.2026.106121_bib38","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1016\/j.neuropharm.2011.12.022","article-title":"The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide","volume":"62","author":"Kanoski","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ebiom.2026.106121_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101407","article-title":"Anorectic and aversive effects of GLP-1 receptor agonism are mediated by brainstem cholecystokinin neurons, and modulated by GIP receptor activation","volume":"55","author":"Costa","year":"2022","journal-title":"Mol Metab"},{"key":"10.1016\/j.ebiom.2026.106121_bib40","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1111\/dom.15184","article-title":"Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: a Phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participants","volume":"25","author":"Pratt","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ebiom.2026.106121_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1210\/clinem\/dgae719","article-title":"Clinical consequences of delayed gastric emptying with GLP-1 receptor agonists and tirzepatide","volume":"110","author":"Jalleh","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ebiom.2026.106121_bib42","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.cell.2015.02.023","article-title":"Neural control of energy balance: translating circuits to therapies","volume":"161","author":"Gautron","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.ebiom.2026.106121_bib43","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s40265-018-0946-y","article-title":"Centrally acting agents for obesity: past, present, and future","volume":"78","author":"Coulter","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.ebiom.2026.106121_bib44","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/j.cell.2016.05.007","article-title":"Mapping of brain activity by automated volume analysis of immediate early genes","volume":"165","author":"Renier","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.ebiom.2026.106121_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2024.104196","article-title":"3D light-sheet fluorescence microscopy in preclinical and clinical drug discovery","volume":"29","author":"Roostalu","year":"2024","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.ebiom.2026.106121_bib46","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.neuron.2020.11.010","article-title":"Area postrema cell types that mediate nausea-associated behaviors","volume":"109","author":"Zhang","year":"2021","journal-title":"Neuron"},{"key":"10.1016\/j.ebiom.2026.106121_bib47","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41586-024-07685-6","article-title":"Dissociable hindbrain GLP1R circuits for satiety and aversion","volume":"632","author":"Huang","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.ebiom.2026.106121_bib48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0093746","article-title":"A novel humanized GLP-1 receptor model enables both affinity purification and Cre-LoxP deletion of the receptor","volume":"9","author":"Jun","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ebiom.2026.106121_bib49","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adp5765","article-title":"The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron","volume":"16","author":"Sloop","year":"2024","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ebiom.2026.106121_bib50","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1210\/en.2013-1934","article-title":"GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody","volume":"155","author":"Pyke","year":"2014","journal-title":"Endocrinology"},{"key":"10.1016\/j.ebiom.2026.106121_bib51","article-title":"Expression profile of the GLP-1 receptor in the gastrointestinal tract and pancreas in adult female mice","volume":"163","author":"Grunddal","year":"2022","journal-title":"Endocrinology"},{"key":"10.1016\/j.ebiom.2026.106121_bib52","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1369\/jhc.2008.951319","article-title":"Expression of the GLP-1 receptor in mouse, rat, and human pancreas","volume":"56","author":"Tornehave","year":"2008","journal-title":"J Histochem Cytochem"},{"key":"10.1016\/j.ebiom.2026.106121_bib53","doi-asserted-by":"crossref","DOI":"10.1242\/dmm.045351","article-title":"3D quantification of changes in pancreatic islets in mouse models of diabetes type I and II","volume":"13","author":"Roostalu","year":"2020","journal-title":"Dis Model Mech"},{"key":"10.1016\/j.ebiom.2026.106121_bib54","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1210\/en.2017-00812","article-title":"Characterization of the Glucagonlike Peptide-1 Receptor in Male Mouse Brain Using a Novel Antibody and In Situ Hybridization","volume":"159","author":"Jensen","year":"2018","journal-title":"Endocrinology"},{"key":"10.1016\/j.ebiom.2026.106121_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102782","article-title":"GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review","volume":"75","author":"Alfaris","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.ebiom.2026.106121_bib56","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.cmet.2013.04.008","article-title":"Pharmacology, physiology, and mechanisms of incretin hormone action","volume":"17","author":"Campbell","year":"2013","journal-title":"Cell Metab"},{"key":"10.1016\/j.ebiom.2026.106121_bib57","article-title":"GIPR antagonist antibodies conjugated to GLP-1 peptide are bispecific molecules that decrease weight in obese mice and monkeys","volume":"2","author":"Lu","year":"2021","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.ebiom.2026.106121_bib58","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1038\/s41422-020-0384-8","article-title":"Structural insights into the activation of GLP-1R by a small molecule agonist","volume":"30","author":"Ma","year":"2020","journal-title":"Cell Res"},{"key":"10.1016\/j.ebiom.2026.106121_bib59","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.jmb.2019.08.009","article-title":"New insights into beta-cell GLP-1 receptor and cAMP signaling","volume":"432","author":"Tomas","year":"2020","journal-title":"J Mol Biol"},{"key":"10.1016\/j.ebiom.2026.106121_bib60","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1111\/dom.14725","article-title":"Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension","volume":"24","author":"Wilding","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ebiom.2026.106121_bib61","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms11905","article-title":"Genetically and functionally defined NTS to PBN brain circuits mediating anorexia","volume":"7","author":"Roman","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.ebiom.2026.106121_bib62","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/nature12596","article-title":"Genetic identification of a neural circuit that suppresses appetite","volume":"503","author":"Carter","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.ebiom.2026.106121_bib63","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1002\/cne.23992","article-title":"Elucidation of the anatomy of a satiety network: focus on connectivity of the parabrachial nucleus in the adult rat","volume":"524","author":"Zs\u00e9li","year":"2016","journal-title":"J Comp Neurol"},{"key":"10.1016\/j.ebiom.2026.106121_bib64","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1038\/npp.2017.150","article-title":"Paraventricular thalamic control of food intake and reward: role of glucagon-like peptide-1 receptor signaling","volume":"42","author":"Ong","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ebiom.2026.106121_bib65","doi-asserted-by":"crossref","first-page":"E472","DOI":"10.1152\/ajpendo.00250.2023","article-title":"Brain access of incretins and incretin receptor agonists to their central targets relevant for appetite suppression and weight loss","volume":"326","author":"Buller","year":"2024","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.ebiom.2026.106121_bib66","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1038\/s41366-025-01859-6","article-title":"Gastrointestinal adverse events associated with GLP-1 RA in non-diabetic patients with overweight or obesity: a systematic review and network meta-analysis","volume":"49","author":"Ismaiel","year":"2025","journal-title":"Int J Obes"},{"key":"10.1016\/j.ebiom.2026.106121_bib67","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/s42255-022-00606-9","article-title":"Hindbrain circuits in the control of eating behaviour and energy balance","volume":"4","author":"Cheng","year":"2022","journal-title":"Nat Metab"},{"key":"10.1016\/j.ebiom.2026.106121_bib68","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/nrgastro.2016.76","article-title":"Vagal neurocircuitry and its influence on gastric motility","volume":"13","author":"Travagli","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.ebiom.2026.106121_bib69","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1210\/en.2008-1479","article-title":"Endogenous hindbrain glucagon-like peptide-1 receptor activation contributes to the control of food intake by mediating gastric satiation signaling","volume":"150","author":"Hayes","year":"2009","journal-title":"Endocrinology"},{"key":"10.1016\/j.ebiom.2026.106121_bib70","first-page":"G920","article-title":"Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms","volume":"273","author":"Imery\u00fcz","year":"1997","journal-title":"Am J Physiol"},{"key":"10.1016\/j.ebiom.2026.106121_bib71","doi-asserted-by":"crossref","first-page":"34","DOI":"10.2337\/db15-0973","article-title":"Knockdown of GLP-1 receptors in vagal afferents affects normal food intake and glycemia","volume":"65","author":"Krieger","year":"2016","journal-title":"Diabetes"},{"key":"10.1016\/j.ebiom.2026.106121_bib72","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ejps.2017.03.020","article-title":"Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species","volume":"104","author":"Jensen","year":"2017","journal-title":"European Journal of Pharmaceutical Sciences"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396426000022?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396426000022?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T02:43:38Z","timestamp":1775097818000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396426000022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":71,"alternative-id":["S2352396426000022"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2026.106121","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Generation and characterisation of a humanised GLP-1 receptor mouse model for translational drug development","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2026.106121","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106121"}}